ClinicalTrials.gg
CompletedNCT05756855Updated Oct 5, 2026Results posted

Young Adults With Violent Behavior During Early Psychosis (Aim 2)

An interventional study of adapted behavioral intervention in Schizophrenia, Schizo Affective Disorder and Schizophreniform Disorders, sponsored by Columbia University. Completed at 1 site in United States. Open to participants aged 16 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Columbia University · Not applicable, Interventional, and Health services research

How we know

Updated Oct 5, 2026Now CompletedResults posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
16 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Schizophrenia by Columbia University — 1 open to participants now, 1 under way, none of them phase 3. Schizophrenia · Columbia University.

Enrollment
6th of 10
12 · median 32
Started
2024
with 1 other
No phase
10 of 10
1 open now
Registered
8th of 10
by date

Among the 10 studies in Schizophrenia by Columbia University, this one is the 6th largest by enrollment, is one of 2 that started in 2024, is one of 10 with no phase, and was the 8th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 10 studies in Schizophrenia by Columbia University is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 16 Years to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Schizophrenia by Columbia University, or all of them as a file.
02

Study summary

This study aims to provide an evidence-based behavioral intervention to reduce violent behavior for individuals experiencing early psychosis.

Read the detailed description

The investigators will conduct an open pilot trial of a behavioral intervention to reduce violent behavior within the OnTrackNY network. The focus of this open pilot is to explore the acceptability and feasibility of the intervention. The study will enroll early intervention service (EIS) clinician - EIS participant dyads. The planned sample size is 3-4 EIS clinicians and 10-16 EIS participants (up to n=16 dyads). This real-world open pilot will provide feedback to help tailor the intervention to the OnTrackNY setting.

03

Conditions studied

  • Schizophrenia
  • Schizo Affective Disorder
  • Schizophreniform Disorders
  • Delusional Disorder
  • Other Specified Schizophrenia Spectrum and Other Psychotic Disorder

Keywords

  • psychosis
  • schizophrenia
  • violence
  • aggression
  • intervention
04

Who can participate

Ages eligible
16 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 16 to 30 who have experienced nonaffective psychosis with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, other specified/unspecified schizophrenia spectrum and other psychotic disorders (International Classification of Disease Clinical Modification (ICD-10-CM) Diagnosis Code F20.x)
  • Receive First Episode Psychosis (FEP) treatment in one of OnTrackNY clinics/sites with an eligible EIS clinicians
  • Willing to participate in research interviews after each study visit during the study period

Exclusion criteria

Exclusion Criteria:

  • Unable to provide
  • Not fluent (speaking, reading, writing) in English
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    behavioral intervention

    This will involve conducting a 12-week open pilot trial (up to n=16 dyads of EIS clinicians-EIS participants) to test the feasibility and acceptability of the adapted Psychological Interventions for Coping with Anger and Schizophrenia: a study of outcomes (PICASSO) intervention in the OnTrackNY setting.

    Behavioral: adapted behavioral intervention

Interventions

  • Behavioraladapted behavioral intervention

    cognitive behavioral therapy based intervention that focuses on anger, violence, and psychosis

    Also known as: PICASSO

06

What researchers measure

Primary outcomes

  1. Mean Acceptability of Intervention Measure (AIM)

    The AIM is a 5-item measure of the acceptability of the intervention, to be completed by EIS clinicians. Scores range from 1-5 with higher score indicating high acceptability.

    Time frame: 12 weeks

  2. Mean Feasibility of Intervention Measure (FIM)

    The FIM is a 5-item measure of the feasibility of the intervention, to be completed by EIS clinicians. Scores range from 1-5 with higher score indicating high feasibility.

    Time frame: 12 weeks

  3. Number of EIS Client Participants in Attendance

    The number of EIS client participants that attend the cognitive behavioral therapy sessions.

    Time frame: 12 weeks

07

Results

Posted Oct 5, 2026

Participant flow

Seven clinician-client dyads (five clinicians and seven clients) were enrolled across participating OnTrackNY sites between March 2024 and June 2025. Three clinicians worked with one client each, and two clinicians worked with two clients each.

Participant flow — Overall Study
MilestoneBRAVE Intervention - Clinician ParticipantsBRAVE Intervention - Client Participants
Started57
Completed55
Not completed02

Outcome measures

PrimaryMean Acceptability of Intervention Measure (AIM)

The AIM is a 5-item measure of the acceptability of the intervention, to be completed by EIS clinicians. Scores range from 1-5 with higher score indicating high acceptability.

Time frame:
12 weeks
Reported as:
Mean · score on a scale
Mean Acceptability of Intervention Measure (AIM)
score on a scaleBRAVE Intervention - Clinician Participants
Mean Acceptability of Intervention Measure (AIM)4.69 ± 0.65
PrimaryMean Feasibility of Intervention Measure (FIM)

The FIM is a 5-item measure of the feasibility of the intervention, to be completed by EIS clinicians. Scores range from 1-5 with higher score indicating high feasibility.

Time frame:
12 weeks
Reported as:
Mean · score on a scale
Mean Feasibility of Intervention Measure (FIM)
score on a scaleBRAVE Intervention - Clinician Participants
Mean Feasibility of Intervention Measure (FIM)4.65 ± 0.65
PrimaryNumber of EIS Client Participants in Attendance

The number of EIS client participants that attend the cognitive behavioral therapy sessions.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of EIS Client Participants in Attendance
ParticipantsBRAVE Intervention - Client Participants
Number of EIS Client Participants in Attendance7

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BRAVE Intervention - Clinician Participants0/5 (0%)0/5 (0%)0/5 (0%)
BRAVE Intervention - Client Participants0/7 (0%)0/7 (0%)0/7 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)BRAVE Intervention - Clinician ParticipantsBRAVE Intervention - Client ParticipantsTotal
Mean34.2 ± 5.523.71 ± 2.328.08 ± 6.57
Sex: Female, Male
Sex: Female, Male(Participants)BRAVE Intervention - Clinician ParticipantsBRAVE Intervention - Client ParticipantsTotal
Female415
Male167
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BRAVE Intervention - Clinician ParticipantsBRAVE Intervention - Client ParticipantsTotal
Hispanic or Latino033
Not Hispanic or Latino549
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BRAVE Intervention - Clinician ParticipantsBRAVE Intervention - Client ParticipantsTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American011
White448
More than one race011
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)BRAVE Intervention - Clinician ParticipantsBRAVE Intervention - Client ParticipantsTotal
United States5712
08

Study locations

1 site
  • New York State Psychiatric Institute
    New York, New York 10032, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Findings from this study will be presented to research peers, clinicians, and the public through Presentations at Scientific Meetings, Regional Research or Educational Meetings, Newsletters and Social Media and Peer-Reviewed Publications. Those events will occur during or at the conclusion of the study.

Time frame: Descriptive and raw data will be submitted on an annual basis. Unpublished de-identified data will be shared within one year after project completion, or when the data are published, whichever is earlier.

Access criteria: Data and materials will be made available for research to investigators working under a Federal Wide Assurance who meet security measures and data use agreement criteria associated with public repositories, including the National Database for Clinical Trials related to Mental Illness (NDCT) and the National Institute of Mental Health (NIMH) Database of Cognitive Training and Remediation Studies (DoCTRS).

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Oct 2025, 18 months.

Results were first posted in Oct 2026, 11 months after primary completion.

Of 763 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 18 months is below that.

Counting every sponsor, half of 776 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Aug 2026 → Oct 2025 and completion Aug 2026 → Oct 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2023
First posted
Mar 6, 2023
StartActual
Mar 19, 2024
Primary completionActual
Oct 13, 2025was Aug 2026
CompletionActual
Oct 13, 2025was Aug 2026
Results first posted
Oct 5, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 5, 2026
Results
Results posted
posted Oct 5, 2026
Primary completion
Aug 31, 2026→Oct 13, 2025 (actual)
Oct 5, 2026
Study completion
Aug 31, 2026→Oct 13, 2025 (actual)
Oct 5, 2026
Enrollment
15→12
Oct 5, 2026
Primary outcomes
1 edited, 2 description edited
What changed in the outcomes
  • EditedNumber of EIS Client Participants in AttendanceTime frame: 12 weeks
  • DescriptionMean Acceptability of Intervention Measure (AIM): how it is measured was reworded
  • DescriptionMean Feasibility of Intervention Measure (FIM): how it is measured was reworded
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Active, not recruiting→Completed
    Results posted
    Primary completion Aug 31, 2026→Oct 13, 2025 (now actual)
    Study completion Aug 31, 2026→Oct 13, 2025 (now actual)
    Enrollment 15→12
    Primary outcomes 1 edited, 2 description edited
    What changed in the outcomes
    • EditedNumber of EIS Client Participants in AttendanceTime frame: 12 weeks
    • DescriptionMean Acceptability of Intervention Measure (AIM): how it is measured was reworded
    • DescriptionMean Feasibility of Intervention Measure (FIM): how it is measured was reworded
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05756855
Responsible party
Paul S Appelbaum (Elizabeth K. Dollard Professor of Psychiatry, Medicine and Law, Columbia University) — Principal investigator
First posted
Mar 6, 2023
Start date
Mar 19, 2024
Primary completion
Oct 13, 2025
Completion
Oct 13, 2025
Results posted
Oct 5, 2026
Last update
Oct 5, 2026

Study contacts

Paul S Appelbaum, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion